121 related articles for article (PubMed ID: 12712431)
1. Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect.
Kim EJ; Bae SK; Kim HJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG
J Pharm Sci; 2003 May; 92(5):1112-24. PubMed ID: 12712431
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
3. Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Lee MH; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Yoo SE; Lee MG
J Pharm Sci; 2003 Jan; 92(1):190-201. PubMed ID: 12486695
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
6. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect.
Yu SY; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG
J Pharm Sci; 2003 Aug; 92(8):1592-603. PubMed ID: 12884246
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim SH; Lee MG
Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.
Shin JH; Choi KY; Kim YC; Lee MG
Antimicrob Agents Chemother; 2004 May; 48(5):1756-62. PubMed ID: 15105131
[TBL] [Abstract][Full Text] [Related]
9. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats.
Kim J; Han KS; Lee JW; Lee MG
Res Commun Mol Pathol Pharmacol; 1998 Nov; 102(2):125-36. PubMed ID: 10100504
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
Han KS; Kim YG; Yoo JK; Lee JW; Lee MG
Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect.
Kim EJ; Kim SO; Lee DH; Lim H; Lee MG
Biopharm Drug Dispos; 2001 Apr; 22(3):119-28. PubMed ID: 11745914
[TBL] [Abstract][Full Text] [Related]
12. Liver and gastrointestinal first-pass effects of azosemide in rats.
Kim J; Kim SH; Lee MG
J Pharm Pharmacol; 1997 Sep; 49(9):878-83. PubMed ID: 9306255
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats.
Kim J; Kim EJ; Han KS; Chang MS; Lee MG
J Pharm Pharmacol; 1999 Sep; 51(9):1031-6. PubMed ID: 10528986
[TBL] [Abstract][Full Text] [Related]
14. Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats.
Lee DY; Kim JY; Kim YC; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2005 Jul; 26(5):173-82. PubMed ID: 15841492
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
16. Stability, blood partition, and pharmacokinetics of a new proton pump inhibitor, YJA-20379-8.
Chung SY; Han KS; Chung YK; Chang MS; Lee MG
Res Commun Mol Pathol Pharmacol; 1998 May; 100(2):187-200. PubMed ID: 9667073
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a new proton pump inhibitor, YJA-20379-8, in rats with 48-hour water deprivation.
Kim HJ; Han KS; Chung YK; Chang MS; Lee MG
Res Commun Mol Pathol Pharmacol; 1998 Aug; 101(2):137-46. PubMed ID: 9821210
[TBL] [Abstract][Full Text] [Related]
18. Intestinal first-pass effect of bumetanide in rats.
Kim EJ; Han KS; Lee MG
Int J Pharm; 2000 Jan; 194(2):193-9. PubMed ID: 10692643
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
20. Oral idazoxan bioavailability in rat. Relevance of intestinal and hepatic first-pass effect.
Vallès J; Pruñonosa J; Menargues A; Nomen M; Obach R
Drug Metab Dispos; 1989; 17(6):673-6. PubMed ID: 2575506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
